157 related articles for article (PubMed ID: 16497087)
21. Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of
Haage P; Kronstrand R; Josefsson M; Calistri S; van Schaik RHN; Green H; Kugelberg FC
Pharmacol Res Perspect; 2018 Jul; 6(4):e00419. PubMed ID: 29992026
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.
Kirchheiner J; Schmidt H; Tzvetkov M; Keulen JT; Lötsch J; Roots I; Brockmöller J
Pharmacogenomics J; 2007 Aug; 7(4):257-65. PubMed ID: 16819548
[TBL] [Abstract][Full Text] [Related]
23. Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study.
Pedersen RS; Damkier P; Brosen K
Clin Pharmacol Ther; 2005 Jun; 77(6):458-67. PubMed ID: 15961977
[TBL] [Abstract][Full Text] [Related]
24. Postmenstrual age and CYP2D6 polymorphisms determine tramadol o-demethylation in critically ill neonates and infants.
Allegaert K; van Schaik RH; Vermeersch S; Verbesselt R; Cossey V; Vanhole C; van Fessem M; de Hoon J; van den Anker JN
Pediatr Res; 2008 Jun; 63(6):674-9. PubMed ID: 18317231
[TBL] [Abstract][Full Text] [Related]
25. Pharmacogenetic aspects of tramadol pharmacokinetics and pharmacodynamics after a single oral dose.
Bastami S; Haage P; Kronstrand R; Kugelberg FC; Zackrisson AL; Uppugunduri S
Forensic Sci Int; 2014 May; 238():125-32. PubMed ID: 24709712
[TBL] [Abstract][Full Text] [Related]
26. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6.
Enggaard TP; Poulsen L; Arendt-Nielsen L; Brøsen K; Ossig J; Sindrup SH
Anesth Analg; 2006 Jan; 102(1):146-50. PubMed ID: 16368820
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic/pharmacodynamic modeling of the antinociceptive effects of (+)-tramadol in the rat: role of cytochrome P450 2D activity.
Garrido MJ; Sayar O; Segura C; Rapado J; Dios-Vieitez MC; Renedo MJ; Troconiz IF
J Pharmacol Exp Ther; 2003 May; 305(2):710-8. PubMed ID: 12606644
[TBL] [Abstract][Full Text] [Related]
28. Tramadol and o-desmethyl tramadol clearance maturation and disposition in humans: a pooled pharmacokinetic study.
Allegaert K; Holford N; Anderson BJ; Holford S; Stuber F; Rochette A; Trocóniz IF; Beier H; de Hoon JN; Pedersen RS; Stamer U
Clin Pharmacokinet; 2015 Feb; 54(2):167-78. PubMed ID: 25258277
[TBL] [Abstract][Full Text] [Related]
29. Post-mortem SNP analysis of CYP2D6 gene reveals correlation between genotype and opioid drug (tramadol) metabolite ratios in blood.
Levo A; Koski A; Ojanperä I; Vuori E; Sajantila A
Forensic Sci Int; 2003 Jul; 135(1):9-15. PubMed ID: 12893130
[TBL] [Abstract][Full Text] [Related]
30. Basic pharmacology relevant to drug abuse assessment: tramadol as example.
Raffa RB
J Clin Pharm Ther; 2008 Apr; 33(2):101-8. PubMed ID: 18315774
[TBL] [Abstract][Full Text] [Related]
31. Rifampicin markedly decreases the exposure to oral and intravenous tramadol.
Saarikoski T; Saari TI; Hagelberg NM; Neuvonen M; Neuvonen PJ; Scheinin M; Olkkola KT; Laine K
Eur J Clin Pharmacol; 2013 Jun; 69(6):1293-301. PubMed ID: 23242004
[TBL] [Abstract][Full Text] [Related]
32. Near-fatal tramadol cardiotoxicity in a CYP2D6 ultrarapid metabolizer.
Elkalioubie A; Allorge D; Robriquet L; Wiart JF; Garat A; Broly F; Fourrier F
Eur J Clin Pharmacol; 2011 Aug; 67(8):855-8. PubMed ID: 21691803
[TBL] [Abstract][Full Text] [Related]
33. Desmetramadol Has the Safety and Analgesic Profile of Tramadol Without Its Metabolic Liabilities: Consecutive Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trials.
Zebala JA; Searle SL; Webster LR; Johnson MS; Schuler AD; Maeda DY; Kahn SJ
J Pain; 2019 Oct; 20(10):1218-1235. PubMed ID: 31005596
[TBL] [Abstract][Full Text] [Related]
34. Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol.
Paar WD; Poche S; Gerloff J; Dengler HJ
Eur J Clin Pharmacol; 1997; 53(3-4):235-9. PubMed ID: 9476037
[TBL] [Abstract][Full Text] [Related]
35. Comparative bioavailability between two Tramadol once-daily oral formulations.
Hernandez-Lopez C; Martinez-Farnos L; Karhu D; Perez-Campos T; Rovira S; Encina G
Methods Find Exp Clin Pharmacol; 2006; 28(6):373-8. PubMed ID: 16894407
[TBL] [Abstract][Full Text] [Related]
36. Assessment of tramadol pharmacokinetics in correlation with CYP2D6 and clinical symptoms.
Ahmadimanesh M; Naeini MB; Rouini MR; Shadnia S; Ghazi-Khansari M
Drug Metab Pers Ther; 2020 Jun; 35(2):. PubMed ID: 32681776
[TBL] [Abstract][Full Text] [Related]
37. Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6-Mediated Drug-Drug Interactions on Tramadol and O-Desmethyltramadol Exposures via Allosteric and Competitive Inhibition.
Long T; Cristofoletti R; Cicali B; Michaud V; Dow P; Turgeon J; Schmidt S
J Clin Pharmacol; 2022 Jan; 62(1):76-86. PubMed ID: 34383318
[TBL] [Abstract][Full Text] [Related]
38. Impact of CYP genotype and inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients.
Tanaka H; Naito T; Sato H; Hiraide T; Yamada Y; Kawakami J
Eur J Clin Pharmacol; 2018 Nov; 74(11):1461-1469. PubMed ID: 30051214
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the Ecstasy influence on tramadol and its main metabolite plasma concentration in rats.
Jamali B; Sheikholeslami B; Hosseinzadeh Ardakani Y; Lavasani H; Rouini MR
Drug Metab Pers Ther; 2017 Sep; 32(3):137-145. PubMed ID: 28917081
[TBL] [Abstract][Full Text] [Related]
40. Population pharmacokinetic analysis of tramadol and
Lee J; Yoo HD; Bae JW; Lee S; Shin KH
Drug Des Devel Ther; 2019; 13():1751-1761. PubMed ID: 31213765
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
